Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Whether strawberry supplementation mitigates the risk for late-life dementia.
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment. The Phase
With oral simnotrelvir/ritonavir treatment in a vaccinated population, COVID-19 symptoms went away about 1.5 days earlier and SARS-CoV-2 viral loads fell, a Chinese placebo-controlled phase